P-3 FACTORS ASSOCIATED WITH AN IMPROVEMENT IN SEQUENTIAL LIVER STIFFNESS MEASURES BY TRANSIENT ELASTOGRAPHY IN MASLD PATIENTS WITH PREDIABETES AND TYPE 2 DIABETES.

No There is increasing evidence that a ≥20% decrease in sequential liver stiffness measurements (ΔLSM) by transient elastography (TE) is associated with a lower risk of long-term liver-related outcomes and mortality in patients with MASLD. Objective: We aimed to evaluate factors associated with ≥20% decrease in ΔLSM in MASLD patients with prediabetes (Pre-DM) and type 2 diabetes (T2DM). MASLD adults with PreDM or T2DM with two consecutive reliable LSMs by transient TE (Fibroscan Touch 502) were included. Clinical, biochemical and elastography data were collected at baseline and follow-up. PNPLA3 (rs738409 C>G) genotypes were determined. A multivariate logistic regression analysis was performed to evaluate the variables independently associated with ≥20% decrease in ΔLSM. All data were analyzed using the statistical package SPSS (vs.24.0,IBM), a p-value < 0.05 was regarded as significant. 294 patients were included (70% female, 60 ± 10 y, 63% with BMI ≥ 30 kg/m2): 14% had PreDM and 86% T2DM. Genotyping of PNPLA3 was identified as CC in 46% and CG+GG in 54%. At the first TE, 10% had LSM > 15kPa [median 7.0 kPa (5.1-10.1)]. Overall, 31% experienced a ≥20% decrease in ΔLSM on a 38 (26-52) months interval. On logistic multivariate regression, the variables independently associated with a ≥20% decrease in ΔLSM were the genotype CC of PNPLA3 (OR 1.71/ 95%CI 1.03-2.85; p=0.038) and final glycated hemoglobin ≤7% (OR 1.75/ 95%CI 1.04-2.94; p=0.034) . Statin use (OR 1.78/ 95%CI 0.99-3.18; p=0.05) had a borderline statistical significance. A clinically significant improvement in LSM is associated with a better glycemic control and the presence of wild-type PNPLA3CC in MASLD patients with PreDM or T2DM. Future prospective studies are needed to determine whether genetic predisposition and factors of clinical importance may confer a reduction in the risk of liver-related outcomes in these high-risk populations.

Authors

Institutions

Publication Details

Journal
Annals of Hepatology
Published
2024-12-01
DOI
https://doi.org/10.1016/j.aohep.2024.101617
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

P-3 FACTORS ASSOCIATED WITH AN IMPROVEMENT IN SEQUENTIAL LIVER STIFFNESS MEASURES BY TRANSIENT ELASTOGRAPHY IN MASLD PATIENTS WITH PREDIABETES AND TYPE 2 DIABETES.

Ana Carolina Cardoso, Nathalie Carvalho Leite, Claudia R.L. Cardoso, Cristiane Alves Villela‐Nogueira et al.
Annals of Hepatology
Liver Disease Diagnosis and Treatment
article

P-3 FACTORS ASSOCIATED WITH AN IMPROVEMENT IN SEQUENTIAL LIVER STIFFNESS MEASURES BY TRANSIENT ELASTOGRAPHY IN MASLD PATIENTS WITH PREDIABETES AND TYPE 2 DIABETES.

Ana Carolina Cardoso, Nathalie Carvalho Leite, Claudia R.L. Cardoso, Cristiane Alves Villela‐Nogueira, Gilles Salles, Lorrane V. Santos
article en

Abstract

No There is increasing evidence that a ≥20% decrease in sequential liver stiffness measurements (ΔLSM) by transient elastography (TE) is associated with a lower risk of long-term liver-related outcomes and mortality in patients with MASLD. Objective: We aimed to evaluate factors associated with ≥20% decrease in ΔLSM in MASLD patients with prediabetes (Pre-DM) and type 2 diabetes (T2DM). MASLD adults with PreDM or T2DM with two consecutive reliable LSMs by transient TE (Fibroscan Touch 502) were included. Clinical, biochemical and elastography data were collected at baseline and follow-up. PNPLA3 (rs738409 C>G) genotypes were determined. A multivariate logistic regression analysis was performed to evaluate the variables independently associated with ≥20% decrease in ΔLSM. All data were analyzed using the statistical package SPSS (vs.24.0,IBM), a p-value < 0.05 was regarded as significant. 294 patients were included (70% female, 60 ± 10 y, 63% with BMI ≥ 30 kg/m2): 14% had PreDM and 86% T2DM. Genotyping of PNPLA3 was identified as CC in 46% and CG+GG in 54%. At the first TE, 10% had LSM > 15kPa [median 7.0 kPa (5.1-10.1)]. Overall, 31% experienced a ≥20% decrease in ΔLSM on a 38 (26-52) months interval. On logistic multivariate regression, the variables independently associated with a ≥20% decrease in ΔLSM were the genotype CC of PNPLA3 (OR 1.71/ 95%CI 1.03-2.85; p=0.038) and final glycated hemoglobin ≤7% (OR 1.75/ 95%CI 1.04-2.94; p=0.034) . Statin use (OR 1.78/ 95%CI 0.99-3.18; p=0.05) had a borderline statistical significance. A clinically significant improvement in LSM is associated with a better glycemic control and the presence of wild-type PNPLA3CC in MASLD patients with PreDM or T2DM. Future prospective studies are needed to determine whether genetic predisposition and factors of clinical importance may confer a reduction in the risk of liver-related outcomes in these high-risk populations.

Annals of HepatologyVol. 29
Universidade Federal do Rio de Janeiro (BR), Universidade Federal do Estado do Rio de Janeiro (BR)
Zero hunger
Openalex Percentile: Top 66%
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.